Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
Ewa Fiorentino-Rozek, Head of Clinical Affairs at AliveDx, shared a post on LinkedIn:
“IVD of the Week: Blood Group Genotyping – Are We Ready for Routine Use?
Blood group genotyping has come a long way in recent years. It started as a specialized tool for identifying rare donors and solving complex antibody cases, but it’s increasingly being talked about as part of routine blood bank practice.
Compared to traditional serology, genotyping can:
– Detect blood group variants that serology can miss
– Improve matching for patients who receive frequent transfusions (like those with sickle cell disease or thalassemia
– Help manage rare donor inventories more effectively
Yet despite all this progress, many labs still rely mostly on serological methods. Making genotyping a routine part of blood banking isn’t simple. There are real hurdles:
– Cost – both for instruments and ongoing reagents
– Integration – adapting workflows and training staff
– Data interpretation – translating genotyping results into clear transfusion decisions
– Guidelines – not all regions have clear recommendations on when or how to implement routine genotyping
I’d love to hear from colleagues across labs, blood services, and industry:
– Is your center already using genotyping routinely, or only for special cases?
– What barriers are slowing down broader adoption where you work?
– Do you think genotyping will become standard practice in the next five years—or is that still further off?
Let’s share real-world experiences and thoughts on how to bridge the gap between promise and practice in blood group genotyping.
________
Hi, I’m Ewa, and I help In Vitro Diagnostics companies bring innovative products to market.
Follow me for insights on IVD regulations, performance evaluation, and industry trends.”
Stay updated with Hemostasis Today.
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 2, 2025, 08:49Why Polycythemia Vera Doesn’t Raise EPO Levels Explained by William Aird
-
Sep 2, 2025, 08:47SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
-
Sep 2, 2025, 08:43Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
-
Sep 2, 2025, 08:14Mirvat Alasnag Discusses OPTION-STEMI Findings Published in The Lancet
-
Sep 1, 2025, 15:31Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
-
Sep 1, 2025, 07:39Flora Peyvandi: Reappraising Hemostasis Testing in Cirrhosis
-
Sep 1, 2025, 07:35Dario Bongiovanni Presents Milestone Discovery on Reticulated Platelets at ESC Congress 2025
-
Sep 1, 2025, 07:19Felice Gragnano: Clopidogrel vs Aspirin for Secondary Prevention in Coronary Artery Disease – Meta-Analysis Shows Superior MACCE Protection
-
Sep 1, 2025, 07:18Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk
-
Aug 31, 2025, 07:10Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin